Structural Determinants of the \( \beta \)-Selectivity of a Bacterial Aminotransferase\(^{\text{[1]}}\)

Gjalt G. Wybenga\(^{1,2} \), Ciprian G. Crismaru\(^{1,3} \), Dick B. Janssen\(^{2} \), and Bauke W. Dijkstra\(^{1,2} \)

From the\(^{1} \)Laboratory of Biophysical Chemistry and \(^{2} \)Department of Biochemistry, University of Groningen, 9747 AG Groningen, The Netherlands

\( \beta \)-Transaminases are promising biocatalysts for the synthesis of \( \beta \)-amino acids. The first three-dimensional structures were obtained of a native \( \beta \)-transaminase and complexes with a keto acid and two covalently bound \( \beta \)-amino acids. Dual functionality of the carboxylate- and side chain-binding pockets allows binding of \( \beta \)- and \( \alpha \)-amino acids.

Significance: These structures may facilitate the development of improved \( \beta \)-amino acid biocatalysts.

Chiral \( \beta \)-amino acids occur as constituents of various natural and synthetic compounds with potentially useful bioactivities. The pyridoxal 5'-phosphate (PLP)-dependent S-selective aminotransferase from Mesorhizobium sp. strain LUK (MesAT) is a fold type I aminotransferase that can be used for the preparation of enantiopure \( \beta \)-Phe and derivatives thereof. Using x-ray crystallography, we solved structures of MesAT in complex with (S)-\( \beta \)-Phe, (R)-3-amino-5-methylhexanoic acid, 2-oxoglutarate, and the inhibitor 2-aminoxyacetic acid, which allowed us to unveil the molecular basis of the amino acid specificity and enantioselectivity of this enzyme. The binding pocket of the side chain of a \( \beta \)-amino acid is located on the 3'-oxygen side of the PLP cofactor. The same binding pocket is utilized by MesAT to bind the \( \alpha \)-carboxylate group of an \( \alpha \)-amino acid. A \( \beta \)-amino acid thus binds in a reverse orientation in the active site of MesAT compared with an \( \alpha \)-amino acid. Such a binding mode has not been reported before for any PLP-dependent aminotransferase and shows that the active site of MesAT has specifically evolved to accommodate both \( \beta \)- and \( \alpha \)-amino acids.

\( \beta \)-Amino acids occur as precursors of many natural and synthetic compounds that display a wide range of pharmacological activities. Altering and improving the pharmacological properties of these compounds critically depend on the availability of \( \beta \)-amino acids and their derivatives as building blocks. Therefore, several strategies for the synthesis of \( \beta \)-amino acids have been explored over the years, involving either synthetic (1, 2) or combined chemoenzymatic (3) methods. However, fully enzyme-based synthesis methods have clear advantages over synthetic or chemoenzymatic methods (4) and have the potential to increase the feasibility of biocatalytic or fermentative routes toward \( \beta \)-amino compounds.

Pyridoxal 5'-phosphate (PLP)\(^{3} \)-dependent aminotransferases (also called transaminases) are attractive for the production of amino acids because they have a broad substrate range, can be highly enantioselective, show a high catalytic activity, and are relatively stable (5). Aminotransferases catalyze the transfer of an amino group from an amino compound to a keto acid. In the first half-reaction, the amino group of the amino compound replaces the covalent Schiff base linkage, or imine bond, between the \( \epsilon \)-amino group of a lysine and the C4A atom of the PLP cofactor, generating an external aldimine (Fig. 1). Lysine-assisted transfer of a proton from the external aldimine to the C4A atom of the cofactor results in a ketimine intermediate, which is hydrolyzed to yield pyridoxamine phosphate (PMP). Subsequently, in the second half-reaction, the amino group of PMP is transferred to a keto acid, which generates a new amino compound, and MesAT can be used to produce (S)-\( \beta \)-Phe from its \( \beta \)-keto acid ethyl ester in a coupled enzyme reaction containing a lipase to generate the keto acid in situ and rac-3-aminobutyric acid as amino donor (8).

\( \beta \)-Amino acids occur as precursors of many natural and synthetic compounds that display a wide range of pharmacological activities. Altering and improving the pharmacological properties of these compounds critically depend on the availability of \( \beta \)-amino acids and their derivatives as building blocks. Therefore, several strategies for the synthesis of \( \beta \)-amino acids have been explored over the years, involving either synthetic (1, 2) or combined chemoenzymatic (3) methods. However, fully enzyme-based synthesis methods have clear advantages over synthetic or chemoenzymatic methods (4) and have the potential to increase the feasibility of biocatalytic or fermentative routes toward \( \beta \)-amino compounds.

Significance: These structures may facilitate the development of improved \( \beta \)-amino acid biocatalysts.

\( \beta \)-Transaminases are promising biocatalysts for the synthesis of \( \beta \)-amino acids. The first three-dimensional structures were obtained of a native \( \beta \)-transaminase and complexes with a keto acid and two covalently bound \( \beta \)-amino acids. Dual functionality of the carboxylate- and side chain-binding pockets allows binding of \( \beta \)- and \( \alpha \)-amino acids.

Significance: These structures may facilitate the development of improved \( \beta \)-amino acid biocatalysts.
Structural Determinants of MesAT β-Selectivity

![Diagram of structural determinants of MesAT](image)

FIGURE 1. Half-reactions catalyzed by MesAT, a β-specific PLP-dependent transaminase. An amino acid ([(S)-β-Phe]) enters the active site of the enzyme (Enz) (step 1), and an external aldimine is generated. Lys-280, a base, abstracts the Cβ proton (step 2) and transfers the proton to the C4A atom (1,3-prototropic shift; not shown), which results in the ketimine intermediate. Hydrolysis of the ketimine intermediate results in the formation of PMP and a keto acid (3-oxo-3-phenylpropanoic acid) (step 3).

nately, the more stable keto ester is a very poor substrate for aminotransferase-mediated conversion to (S)-β-Phe.

Information on three-dimensional structures of β-amino
transferases is currently lacking. To enable rational protein
engineering approaches for improving the activity of the
enzyme for application in the biosynthesis of β-amino acids, we
have elucidated the crystal structure of MesAT in the native
state, as well as in complex with β-amino acids, a keto acid, and
an inhibitor. The structure of the enzyme conforms to a fold
that conforms to a fold
M type I aminotransferase structure, but the hydrophobic binding
pocket is located on the 3'-oxygen side of the PLP cofactor
rather than on its phosphate side as found in other aminotrans-
ferases. On the other hand, an α-amino acid binds in a normal
orientation, with the α-carboxylate on the 3'-oxygen side and
the side chain of the amino acid on the phosphate side of the
PLP cofactor. The architecture of the active site explains how
MesAT can accept β- and α-amino acids (8), whereas the aro-
matic α-amino acid aminotransferase (AroAT) from Paracoc-
cus denitrificans (11) and most other aminotransferases accept
only α-amino acids. The structure also explains the stereo pref-
erence of the enzyme for α- and β-amino acids.

EXPERIMENTAL PROCEDURES

Protein Expression and Purification—The MesAT gene was
codon-optimized for E. coli, synthesized by DNA2.0, Inc., and
cloned into the expression plasmid pET28b+ with an N-termi-
nal His6 tag using NdeI/HindIII restriction sites. After transfor-
mation into E. coli BL21(DE3), cells were grown at 37 °C in 1.4
liters of Terrific broth/sorbitol medium (12) containing 50
mM of Terrific broth/sorbitol medium (12) containing 50
mM NaCl, 20 mM imidazole, 1 mg of DNase I (Roche Applied
Science), and one complete EDTA-free prote-
some inhibitor tablet (Roche Applied Science). The cells
were disrupted at 4 °C by sonication, followed by centrifugation
at 31,000 g for 1 h at 4 °C.

The supernatant was applied to a HisTrap HP affinity chroma-
tography column (GE Healthcare), and after washing, MesAT was eluted with 15 column volumes of a linear gradient of 20–500 mM imidazole in elution buffer (20 mM Tris-HCl (pH 8.0) and 500 mM NaCl). The fractions corresponding to the peak were pooled, and the imidazole was removed by buffer exchange using a HiPrep 26/10 desalting column (GE Healthcare) equilibrated with 25 mM Tris-HCl (pH 8.0) and 0.01% (v/v) β-mercaptoethanol. The resulting protein fractions were applied to a Q-Sepharose HP anion exchange column (GE Healthcare) and eluted with 15 column volumes of a linear gradient of 0–1 M NaCl in 25 mM Tris-HCl (pH 8.0). The fractions containing active enzyme were pooled, concentrated (Ultracel, M, 30,000 cutoff, Amicon), and applied to a Superdex 200 10/300 GL size exclusion chromatography column (GE Healthcare) equilibrated with 20 mM Tris-HCl (pH 8.0) containing 200 mM NaCl. After elution, the fractions corresponding to the protein peak were pooled, concentrated (Amicon), and dialyzed overnight against buffer containing 20 mM Tris-HCl (pH 7.5). The sample was subsequently concentrated to 10 mg/ml as judged by a protein assay, and the purity of the sample was checked with silver-stained SDS-polyacrylamide gels using a PhastSystem (GE Healthcare).

Mutagenesis—The R412A mutant gene of MesAT (supple-
mental Table S2) was constructed by site-directed mutagenesis (QuikChange, Stratagene) and transformed into E. coli DH5α ElectroMAX electrocompetent cells (Invitrogen). For overex-
pression, E. coli BL21(DE3) was used. The mutant construct
was confirmed by sequence analysis (GATC Biotech).

Protein Crystallization—A Mosquito crystallization robot
(TTP LabTech) was used to search for suitable crystallization
conditions. Crystallization experiments were set up at 20 °C.
Crystals were found in a JCSG+ Suite (Qiagen) condition con-
taining 0.1 M HEPES (pH 7.5), 8% (v/v) ethylene glycol, and 10%
(w/v) PEG 8000. After optimization, it was found that this was
also the optimal condition for crystal growth, with crystals
reaching sizes of 80 × 50 × 30 μm. Crystals were transferred to a
cryoprotection solution consisting of mother liquor with 20%
(v/v) ethylene glycol. This was done in four steps of 5 min each, starting with a solution containing 2% (v/v) ethylene glycol, followed by solutions of 5, 10, and finally 20% (v/v) ethylene glycol. Crystals from this last solution were cryo-cooled in liquid nitrogen. For amino acid binding studies, the same steps were followed, but with the cryoprotection solutions supplemented with 2, 5, 10, and 20 mM (S)-β-Phe (PepTech Corp.), (R)-3-amino-5-methylhexanoic acid (Flurochem), 2-oxoglutarate disodium salt (Fluka), or 2-aminoxyacetic acid (AOA) (Aldrich).

**Diffraction Data Collection and Processing**—Diffraction data were collected at beamlines ID14-1 and ID14-2 of the European Synchrotron Radiation Facility (ESRF, Grenoble, France) and at beamline X13 of the European Molecular Biology Laboratory Outstation at the Deutsches Elektronen-Synchrotron (DESY, Hamburg, Germany). Reflections were indexed and integrated using XDS (13), and scaling and merging of the data were done with the program SCALA (14) from the CCP4 Software Suite (15). Phaser (16) was used for molecular replacement with a mixed input model generated by the FFA503 server (17) on the basis of the structures of glutamate-1-semialdehyde 2,1-amino-mutase from *Thermus thermophilus* strain HB8 (Protein Data Bank code 2E7U), α-phenylglycine aminotransferase from *Pseudomonas stutzeri* strain ST-201 (code 2CY8), and 4-amino-nobutyrate aminotransferase from pig (code 1OHV (18)).

The resulting model was subjected to successive rounds of automatic model building with ARP/wARP (19), followed by manual model building in Coot (20). REFMAC5 was used for refinement of the atomic coordinates and atomic B-factors (21). Data collection and refinement statistics are given in supplemental Table S3. After refinement, the model was validated with MolProbity (22). Stereochemical restraints for the amino acid analogs were generated using the PRODRG2 server (23). Root mean square deviations (r.m.s.d.) were calculated with the RMSDcalc tool of the CaspR server (24), and structural homologs of MesAT were obtained from the Dalil server (25). PISA from the CCP4 Software Suite was used for protein interface analysis (26). Simulated annealing composite omit maps where generated with PHENIX (27). Chemical structure drawings were made using the ChemDraw program (CambridgeSoft), and PyMOL (28) was used to generate images of the protein structure.

**Enzyme Assay and Analytical Methods**—Aminotransferase assays were performed with 10 mM amino donor ((S)-β-Phe), 10 mM amino acceptor (pyruvate), and enzyme at 37 °C in 50 mM MOPS (pH 7.6) containing 50 µM PLP (Acros Organics). Samples were taken at different times and treated according to the following procedure: to 50 µl of sample was added 50 µl of 2 M HCl to quench the reaction. The sample was left on ice for 5 min and neutralized by adding 45 µl of 2 M NaOH, followed by adding 50 µl of demineralized water. In an HPLC autosampler (Jasco), 1-µl sample was mixed with 2 µl of o-phthalaldehyde (Sigma) solution (15 mg of o-phthalaldehyde was dissolved in 50 µl of absolute ethanol, which was then mixed with 4.42 ml of 0.4 M sodium borate (pH 10.4), 15 µl of 30% (w/v) Brij 35 (Fluka), and 11 µl of β-mercaptoethanol) and 5 µl of 0.4 M sodium borate (pH 10.4). The o-phthalaldehyde-derivatized samples were analyzed by HPLC using a Alttech Adsorbosphere C18 column (5 µm, 4.6 × 100 mm) in a Jasco HPLC system. Separation of o-phthalaldehyde-derivatized imines was achieved at room temperature at a flow rate of 1 ml/min using a gradient of eluent A (5% THF in 20 mM sodium acetate (pH 5.5)) and eluent B (99% pure CH3CN) as follows: start with 100:0 eluent A/eluent B for 5 min; change from 100:0 to 80:20 in 7 min; continue with 80:20 for 4 min; change from 80:20 to 40:60 in 8 min; continue with 40:60 for 6 min; change from 40:60 to 100:0 in 2 min; and finally continue for 5 min at 100:0 for re-equilibration of the column. The eluate was analyzed by UV light (338 nm) using a Jasco UV-2075 Plus detector and a Jasco FP-920 fluorescence detector (350 nm excitation and 450 nm emission). Retention times for derivatized L-α-alanine and (S)-β-Phe were 7.7 and 23.2 min, respectively. One unit of enzyme activity is defined as the amount of enzyme that produces 1 µmol/min alanine from 10 mM pyruvate (sodium salt; Fluka) and 10 mM (S)-β-Phe (Acros Organics).

To determine the $V_{\text{max}}$ and $K_m$ values of the R412A mutant of MesAT, initial rate assays were done with varying concentrations of (S)-β-Phe or pyruvate, fixing the non-variant substrate at 10 mM. The reactions were started by adding 680 µg of purified protein and incubating at 37 °C. Inhibition studies were performed by preincubating the reaction mixture (lacking (S)-β-Phe but containing 40 µg of wild-type enzyme) with 5 mM AOA or 5 mM DL-proparglyglycine (2-amino-4-pentaerythric acid; Sigma-Aldrich) for 5 min, after which (S)-β-Phe was added.

**RESULTS**

**Overexpression, Purification, and Enzyme Activity Measurements of Wild-type and R412A MesAT**—Previously, an overexpression system of MesAT was reported that gave a yield of 1.4 mg of pure protein/liter of culture (8). To obtain enhanced expression, we used a codon-optimized synthetic gene that was equipped with an N-terminal His tag, cloned it under the control of the T7 promoter in a pET vector, and cultivated the transformed E. coli BL21(DE3) cells in Terrific broth/sorbitol medium at 17 °C. This resulted in an expression level that allowed the isolation of ~10 mg of pure enzyme/liter of culture (supplemental Table S1). The specific activity of the purified wild-type enzyme was 1.6 units/mg, which is similar to what was reported previously (8).

**Structure Determination of MesAT**—The holoenzyme crystallizes in space group C2 with three molecules (chains A, B, and C) per asymmetric unit. The three-dimensional structure of MesAT was elucidated at 2.5 Å resolution by molecular replacement and refined at 1.65 Å resolution. No density is defined for the first 30 N-terminal residues and the C-terminal residue Met-445. The three molecules are very similar to each other, with r.m.s.d. values for the C backbone of 0.2–0.25 Å. The three molecules form 1.5 dimer in the asymmetric unit; one boring asymmetric unit related by crystallographic 2-fold symmetry. Both dimers are very similar, with r.m.s.d. values for the Ca atom positions of ~0.2–0.25 Å. The three molecules form 1.5 dimer in the asymmetric unit; one dimer consists of chains A and B (supplemental Fig. S1), and the other dimer is made up of chain C and a chain C from a neighboring asymmetric unit related by crystallographic 2-fold symmetry. Both dimers are very similar, with r.m.s.d. values in the order of 0.2 Å (Ca atoms). The two chains in the dimer interact tightly, burying a surface area of ~4400 Å², which is one-quarter of their total surface area. The presence of dimers in the
Structural Determinants of MesAT β-Selectivity

FIGURE 2. Stereo figures of simulated annealing composite 2mFo−DFc omit maps contoured at 1σ. A, (S)-β-Phe (magenta) bound to the PLP cofactor. For clarity, Tyr-172 has been omitted here and in B–D. B, (R)-3-amino-5-methylhexanoic acid (magenta). For clarity, Ala-312 has been omitted here as well as in C and D. C, 2-oxoglutarate (magenta) bound in the active site of MesAT. LLP, 2-lysine 3-hydroxy-2-methyl-5-phosphonoxyethylpyridin-4-ylmethane, the internal aldimine. D, AOA (magenta), a β-alanine mimic, bound in the active site of MesAT.

crystal is in agreement with the occurrence of MesAT dimers in solution (10).

Structure of the MesAT Monomer—The MesAT monomer has a curved shape and consists of a PLP-binding domain (residues 112–334) and a domain formed by the N and C termini of the polypeptide chain (NC-domain; residues 1–111 and 335–445) (supplemental Fig. S1). These two domains line a cleft into which the PLP cofactor protrudes. The monomer contains 11 α-helices (of at least two or more turns) and 13 β-strands that form a mixed central seven-stranded β-sheet in the large domain and 2 three-stranded antiparallel β-sheets in the NC-domain (supplemental Fig. S1). The overall structure is similar to that of aspartate aminotransferase, the archetypical representative of fold type 1 aminotransferases (Z-score of 21, r.m.s.d. of 4.2 Å for 309 Cα atoms, and 16% sequence identity; Protein Data Bank code 1BKG) (29, 30), and AroAT from P. denitrificans (Z-score of 21, r.m.s.d. of 4.8 Å for 326 Cα atoms, and 15% sequence identity; code 1AY4) (11, 31), which is specific for L-α-amino group of Lys-280. The amide protons of Gly-145, Thr-146, and Thr-314 (from monomer B in the case of the AB dimer) anchor the phosphate group of the PLP cofactor to the protein backbone. The pyridine ring of the PLP cofactor is stacked between Val-255 (at the si-face of the pyridine ring (32)) and Tyr-172 (at the re-face of the pyridine ring). The nitrogen atom of the pyridine ring is in hydrogen bonding distance of Asp-253. These interactions keep the PLP cofactor secured in the active site.

Binding of (S)-β-Phe—To analyze how (S)-β-Phe binds in the active site, a crystal structure of MesAT with bound (S)-β-Phe was solved at 1.7 Å resolution. (S)-β-Phe binds covalently to the PLP cofactor via its β-amino group, replacing the imine bond between the e-amine of Lys-280 and the C4A atom of the PLP cofactor (Fig. 2A). It binds with an estimated occupancy of ~80% in the three subunits. The carboxylate group of (S)-β-Phe has a salt bridge interaction with the Ne and Nη2 atoms of Arg-54. The aromatic ring of (S)-β-Phe is bound between the side chains of Tyr-89 and Tyr-172 with edge-to-face interactions (Fig. 2A) and also has van der Waals interactions with Ile-56, Ala-225, Met-256, and Met-414 from monomer A and with Ala-312 from monomer B; these residues line a hydrophobic binding pocket that is capped by Arg-412 (monomer A). Thus, residues from both monomers A and B contribute to the binding of the aromatic side chain of (S)-β-Phe. The side chain amino group of Lys-280 is close to the Cβ R-proton of (S)-β-Phe (3.3 Å), in agreement with its role in proton transfer (Fig. 1). The binding of (S)-β-Phe does not induce large-scale conformational changes or domain movements in MesAT. Only local conformational changes have occurred (see “Discussion”).

In monomer A, a second (S)-β-Phe molecule is present in a surface pocket, with its aromatic ring stacked between Leu-269 and Leu-368. Its carboxylate and amino groups point into the solvent and do not interact with the protein. However, in the surface pockets of monomers B and C, electron density is present only for the aromatic ring of an (S)-β-Phe molecule, but not for the amino and carboxylate groups. From this, we conclude that (S)-β-Phe binds nonspecifically in this surface pocket.

Binding of (R)-3-Amino-5-methylhexanoic Acid—To investigate how an aliphatic β-amino acid such as (R)-3-amino-5-methylhexanoic acid (8) binds in the active site, a 1.95 Å resolution crystal structure was determined of MesAT in complex with this compound. (R)-3-Amino-5-methylhexanoic acid...
TABLE 1
Specific activity at 37 °C of wild-type MesAT and the R412A mutant using (S)-β-Phe as amino donor and pyruvate as amino acceptor

<table>
<thead>
<tr>
<th>MesAT</th>
<th>Specific Activity</th>
<th>Relative Activity</th>
<th>(S)-β-Phe</th>
<th>Pyruvate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>units/mg %</td>
<td>K&lt;sub&gt;m&lt;/sub&gt; mmol</td>
<td>k&lt;sub&gt;cat&lt;/sub&gt;/K&lt;sub&gt;m&lt;/sub&gt; s&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>K&lt;sub&gt;i&lt;/sub&gt; mmol</td>
</tr>
<tr>
<td>WT</td>
<td>1.6 100</td>
<td>1.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>1.3</td>
<td>11</td>
</tr>
<tr>
<td>R412A</td>
<td>6.0 10&lt;sup&gt;-3&lt;/sup&gt; 0.4</td>
<td>0.29 5 10&lt;sup&gt;-3&lt;/sup&gt;</td>
<td>2 10&lt;sup&gt;-2&lt;/sup&gt;</td>
<td>47 109 4.1 10&lt;sup&gt;-2&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>a</sup> Adopted from Kim et al. (8).

Analysis of the 1.9 Å resolution crystal structure of MesAT with bound AOA (Fig. 2D) shows that the amino group of AOA binds covalently to the C4<sub>A</sub> atom of PLP, as has also been observed for the interaction of AOA with aspartate aminotransferase (38). The ether oxygen atom (O<sub>1</sub>) is close to Lys-280 (2.9 Å), and the carboxylate group binds via a salt bridge to the Ne and N<sub>η2</sub> atoms of Arg-54. The binding of AOA to the PLP cofactor is irreversible; the amine–O<sub>1</sub> bond cannot be weakened by Lys-280. Binding of AOA to the PLP cofactor thus prevents PMP formation and thereby inhibits aminotransferase activity. No significant conformational changes are observed upon AOA binding.

**DISCUSSION**

**Structure of MesAT**—The structure of MesAT presented here is the first structure of a transaminase with specificity toward β-amino acids as well as α-amino acids. The structure of the enzyme is similar to that of aspartate aminotransferase (39), the archetypical fold type I aminotransferase. The enzyme assembles into a homodimer, in which residues from both monomers A and B contribute to the binding of amino acids and their respective oxo acid substrates. In contrast to aspartate aminotransferase, the binding of ligands does not induce large domain movements. Structural changes that do occur in MesAT upon substrate/inhibitor binding are localized to the active site and consist of a 16° rotation of the pyridine ring of the PLP cofactor upon formation of the external aldime. This rotation liberates Lys-280 and allows it to function as the proton-transferring lysine. Another structural change is the rearrangement of the Arg-412 side chain, also known as the arginine switch (33), upon binding of 2-oxoglutarate (mentioned above).

**Different Binding Modes of (S)-β-Phe, (R)-3-Amino-5-methylhexanoic Acid, and 2-Oxoglutarate**—The way in which 2-oxoglutarate binds in the active site of MesAT and the manner in which (S)-β-Phe and (R)-3-amino-5-methylhexanoic acid bind are very different. The side chains of (S)-β-Phe (Fig. 2A) and (R)-3-amino-5-methylhexanoic acid (Fig. 2B) bind in a pocket on the 3′-oxygen side of the PLP cofactor, which we denote the O-pocket. However, the side chain of the α-keto acid 2-oxoglutarate, a model for the α-amino acid l-glutamate, binds with its γ-carboxylate group on the phosphate side of the PLP cofactor (Fig. 2C), in the P-pocket. Thus, MesAT has two distinct side chain-binding pockets, one for the side chains of β-amino acids (O-pocket) (Fig. 3) and one, on the other end of the active site, for the side chains of α-keto acids and presumably also α-amino acids (P-pocket) (Fig. 3). The enzyme has also two carboxylate-binding pockets; one, involving Arg-54 in the P-pocket, binds the α-carboxylate group of β-amino acids and AOA, a β-alanine mimic (Fig. 2D), whereas the other, which
Structural Determinants of MesAT β-Selectivity

FIGURE 3. Comparison of the active site architectures of the β-aminotransferase MesAT (A and B) and the α-aminotransferase AroAT (C and D). A and B, surface renditions of the active site of MesAT bound to (S)-β-Phe (magenta) and to 2-oxoglutarate (magenta), respectively. C and D, surface renditions of the active site of AroAT bound to 3-phenylpropionate (magenta) based on Protein Data Bank code 1AY8 (31) and to maleate (magenta) based on code 1AYS (31), respectively. The positions of the PLP cofactor and Arg-412 and Arg-386 in the active sites of MesAT and AroAT, respectively, are similar. Arg-412 represents the arginine switch of MesAT, and Arg-292 represents the arginine switch of AroAT. LLP, 2-lysine 3-hydroxy-2-methyl-5-phosphonoxyethylpyridin-4-ylmethane, the internal aldimine. See “Discussion” for explanation of the P-pocket (P) and O-pocket (O).

contains Arg-412 in the O-pocket, binds the α-carboxylate of α-keto acids such as 2-oxoglutarate (Fig. 2C). As a consequence, an α-amino acid and a β-amino acid have very different binding modes in MesAT (Fig. 3, A and B).

Intriguingly, the O-pocket that binds the aliphatic and hydrophobic side chain of β-amino acids also binds the α-carboxylate group of α-keto acids and presumably also of α-amino acids. This dual functionality is made possible by a switch in position of the Arg-412 side chain, the arginine switch residue (33). When a β-amino acid binds, the Arg-412 side chain is oriented away from the active site, providing space in the O-pocket for the hydrophobic side chain of the β-amino acid (Fig. 2, A and B). This orientation of Arg-412 is stabilized by a hydrogen bond of its side chain Nδ atom to the carbonyl oxygen atom of Ala-225 (monomer B) (data not shown). In contrast, upon 2-oxoglutarate binding, the side chain of Arg-412 switches back toward the hydrophobic O-pocket (Fig. 2C); the hydrogen bond with Ala-225 is broken, and Arg-412 now has a salt bridge interaction with the α-carboxylate of 2-oxoglutarate. In this way, the Arg-412 side chain allows the enzyme to accept both α-amino/α-keto acids and aliphatic or aromatic β-amino/β-keto acids in the same active site. Because of the dual functionality of the active site pockets of MesAT, we prefer to use O- and P-pocket (rather than L- and S-pocket) nomenclature, which reflects the presumed size of these pockets (40).

Foraminotransferase activity, Arg-412 is virtually essential, as reflected by the 870- and 55-fold reduction of the catalytic efficiencies for pyruvate and (S)-β-Phe, respectively, upon mutation of this residue to Ala (Table 1). Whereas the decreased apparent $K_{m}$ for (S)-β-Phe can be due to the reduced catalytic rate at 10 mM pyruvate, the increased $K_{m}$ for pyruvate strongly supports that Arg-412 is important for binding pyruvate through electrostatic interactions with its carboxylate.

Comparison of MesAT and AroAT—To investigate how MesAT differs from an aminotransferase that accepts only α-amino acids, the MesAT structures were compared with AroAT from P. denitrificans (11). In both enzymes, the PLP cofactor has a similar position and orientation. In contrast to MesAT, AroAT has a single α-carboxylate-binding pocket, and charged as well as uncharged α-amino acids bind with their α-carboxylate groups to Arg-386 in the O-pocket (Fig. 3, C and D). In MesAT, the α-carboxylate group of (S)-β-Phe binds to Arg-54 in the P-pocket, whereas the side chain of (S)-β-Phe is bound in the O-pocket (Fig. 3A). As a consequence, in MesAT, β-amino acids bind in a reverse orientation in comparison with the substrates of AroAT (Fig. 3, A, C, and D). Moreover, the arginine switch of MesAT (Arg-412) is located in the O-pocket of the enzyme, whereas it binds the α-carboxylate group of an α-amino acid, whereas in AroAT, the arginine switch (Arg-292) is located in the P-pocket of the enzyme and binds the side
chain carboxylate group of α-amino/α-keto acids (Fig. 3, A–D). These differences between MesAT and AroAT show that although these enzymes share the same fold, the architectures of their active sites are very different. In MesAT, the active site architecture has evolved to accommodate β-amino acids while retaining the ability to accommodate α-amino/α-keto acids.

**Covalent Adducts in the Active Site of MesAT Represent External Aldimine Intermediates**—Structures obtained from crystals soaked with (S)-β-Phe and (R)-3-amino-5-methylhexanoic acid show that covalent PLP–β-amino acid adducts have formed in the active site of MesAT (Fig. 2, A and B). These adducts represent external aldime intermediates because the Nβ, Cα, Cβ, and Cγ atoms are not coplanar, as would occur in the ketimine intermediate (Fig. 1). The non-coplanarity of the Nβ, Cα, Cβ, and Cγ atoms suggests that the reaction has stopped before abstraction of the Cβ proton.

Different explanations for the trapping of the external aldimine may be considered. Proton abstraction is most efficient if, in the transition state, the bond to be broken is oriented perpendicular to the plane of the PLP ring system (41). The crystal structures indicate that the Cβ proton is indeed nearly perpendicular to the PLP plane, deviating 20–30° from the perpendicular position. Such a deviation is probably not sufficient to fully prevent proton abstraction.

Another explanation may be related to the observation that in none of the external aldime intermediate-bound structures density is present for a hydrolytic water molecule near the Cβ atom that could convert the ketimine intermediate into the pyridoxamine intermediate (Fig. 1). The equilibrium of the aminotransferase reaction in the crystal structure of MesAT may thus lie toward the external aldime intermediate rather than the ketimine intermediate, which could explain why the external aldime intermediates of (S)-β-Phe and (R)-3-amino-5-methylhexanoic acid are trapped.

**Enantioselectivity of MesAT—**MesAT is enantioselective toward the β-amino acids (S)-β-Phe, (R)-3-amino-5-methylhexanoic acid, and (R)-3-amino-n-butyric acid (8). These preferred enantiomers have the same stereo configuration of functional groups on the Cβ atom as (S)-β-Phe. The preference for these enantiomers can be fully explained by the architecture of the active site, which forces these substrates to bind in an orientation in which the carboxylate group binds to Arg-54 in the P-pocket and the side chain in the O-pocket, followed by addition of an amino group at the si-face of the β-carbon of the β-keto acid. The insights obtained from the three-dimensional structure of MesAT upon its interaction with α- and β-amino/ keto acids may facilitate structure-based protein engineering efforts to enhance the biocatalytic potential of β-transaminases for the production of β-amino acids of pharmacological interest.

Acknowledgments—We acknowledge the ESRF and the EMBL Outstation at DESY for provision of synchrotron radiation facilities. We thank the ID14-1 and ID14-2 (ESRF) and X13 (DESY) beamline staff for assistance.

REFERENCES

Structural Determinants of MesAT β-Selectivity


